Interleukin-6 overexpression as a marker of malignancy in human gliomas
Interleukin-6 overexpression as a marker of malignancy in human gliomas
复制标题
DOI：
10.3171/jns.2001.94.1.0097
复制
发表时间：
2001-01-01
影响因子：
4.1
通讯作者：
Verrelle, P
中科院分区：
文献类型：
--
作者：
Rolhion, C;Penault-Llorca, F;Verrelle, P
Object.多形性胶质母细胞瘤（GBM）生长迅速，与其他胶质瘤类型和级别相比，对治疗具有高度抗性。因此，鉴定这些肿瘤中可能代表新的治疗靶点的侵袭性标志物是主要的兴趣。白细胞介素（IL）-6经常在神经胶质瘤中产生，并且鉴于其多种性质，可以被认为是候选标记物。IL-6的表达可能参与细胞生长、对化疗和放疗的抗性（通过抗凋亡途径）和血管生成。进行本研究以检验该假设并评估IL-6作为治疗GBM的靶点的适用性。作者研究了IL-6基因表达水平之间的关系，通过半定量逆转录聚合酶链反应和确定各种组织学类型和等级在一系列的59个胶质瘤中进行评估。结果发现，GBM中IL-6的表达水平显著高于其他类型的胶质瘤（p < 0.001）。免疫组化分析显示IL-6主要由恶性细胞和少数血管内皮细胞产生。结论.从这些发现可以推断，IL-6基因表达与胶质瘤的侵袭性有关，并且IL-6可能在GEM行为中起核心作用。因此，白细胞介素-6可以被认为是治疗GBM的一个新的潜在靶点。
Object. Glioblastomas multiforme (GBMs) grow rapidly and are highly resistant to treatment compared with other glioma types and grades. Consequently, it is of major interest to identify markers of aggressiveness in these tumors that could represent new therapeutic targets. Interleukin (IL)-6 is frequently produced in gliomas and, given its manifold properties, could be considered as a candidate marker. Expression of IL-6 may be involved in cell growth, resistance to chemotherapy and radiotherapy (via an antiapoptotic pathway), and angiogenesis. This study was conducted to test this hypotheses and to evaluate the suitability of IL-6 as a target in the treatment of GBMs.Methods. The authors studied the relationship between the level of IL-6 gene expression as assessed using semiquantitative reverse transcription-polymerase chain reaction and by determining various histological types and grades in a series of 59 gliomas. It was found that GBMs displayed a significantly higher level of IL-6 expression than other types of glioma (p < 0.001). Immunohistochemical analysis revealed that IL-6 was produced mainly by malignant cells and a few vascular endothelial cells. Conclusions. It can be inferred from these findings that IL-6 gene expression is related to glioma aggressiveness and that IL-6 may play a central role in GEM behavior. Interleukin-6, therefore, could be considered as a new potential target in the treatment of GBMs.